Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · IEX Real-Time Price · USD
1.400
-0.070 (-4.76%)
At close: Jul 19, 2024, 4:00 PM
1.460
+0.060 (4.29%)
Pre-market: Jul 22, 2024, 8:23 AM EDT
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 130 employees as of December 31, 2023. The number of employees increased by 23 or 21.50% compared to the previous year.
Employees
130
Change (1Y)
23
Growth (1Y)
21.50%
Revenue / Employee
$2,569
Profits / Employee
-$543,985
Market Cap
54.53M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130 | 23 | 21.50% |
Dec 31, 2022 | 107 | 35 | 48.61% |
Dec 31, 2021 | 72 | 24 | 50.00% |
Dec 31, 2020 | 48 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
Atara Biotherapeutics | 225 |
Turnstone Biologics | 80 |
Passage Bio | 58 |
Aerovate Therapeutics | 51 |
LAVA Therapeutics | 37 |
Immix Biopharma | 17 |
Ocuphire Pharma | 14 |
BRNS News
- 5 weeks ago - Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewsWire
- 6 weeks ago - Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B - GlobeNewsWire
- 2 months ago - Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 2 months ago - Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - GlobeNewsWire
- 4 months ago - Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 7 months ago - Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - GlobeNewsWire
- 7 months ago - New partnership aims to advance vaccine against MERS coronavirus - GlobeNewsWire